Gapping up
In reaction to strong earnings/guidance:
- NSIT +20.2%, KKR +9.3%, APRN +9%, LOGI +8.9%, TEVA +8.3%, AAC +6.2%, DATA +6.2%, EXEL +6.2%, OMF +6%, DXCM +5%, CZR +4.8%, CRIS +4.5%, FMC +4.2%, MIC +3.9%, GIL +3.8%, BAND +3.4%, LADR +3.3%, HCC +3.3%, KHC +3.3%, MTOR +3.3%, SYNL +3.2%, OCLR +3.1%, EXK +3%, CHD +2.8%, QGEN +2.7%, MET +2.7%, FMI +2.5%, BZH +2%, REGN +2%, EZPW +1.8%, CXW +1.3%, CFX +1.3%, GPN +1.3%, FMSA +1.2%, MSGN +1.2%, NYLD +1.1%, TEP +1.1%, S +1%, APO +1%, WLK +0.9%
M&A news:
- MTGE +7.2% (to be acquired by Annaly Capital (NLY) for $19.65/sharein cash and shares of Annaly common stock)
Other news:
- MRK +2.4% (Phase 3 KEYNOTE-407 trial investigating KEYTRUDA meets secondary endpoint )
- CLLS +2.2% (submits an IND application to the FDA requesting approval to initiate a Phase 1 clinical trial for UCART22 for the treatment of B-cell acute lymphoblastic leukemia )
- ACIA +1.4% (authorized the repurchase of up to $60 mln of common stock through December 31, 2018)
- FIVN +1.3% (commences $200 mln offering of convertible senior notes due 2023)
- SPPI +1.3% (announces licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to certain methods of use of poziotinib)
Analyst comments:
- NVDA +1% (upgraded to Overweight from Equal Weight at Barclays)
- DE +0.7% (upgraded to Buy from Neutral at BofA/Merrill)
- MPC +0.5% (upgraded to Buy from Hold at Jefferies)